← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Cabot's FY2025 revenue, net income, and FCF fell, but margins and equity improved while cash returns stayed large.
The read at a glance✓ Audited against SEC data
- Business mix — Specialty chemicalsNote
- Revenue — $3.71B, -7.0%Watch
- Net income — $331.0M, -12.9%Watch
- FCF — $391.0M, -13.3%Watch
- Margins — Operating margin 16.73%, +136 bpsOK
- Insiders — 0 purchases and 1 saleWatch
- Accounting — Altman grey; EQ safeNote
Business
Cabot is a global specialty chemicals and performance materials company built around reinforcing carbons, specialty carbons, conductive additives, fumed metal oxides, inkjet colorants, and aerogel.
Where the revenue comes from
Fiscal 2025, as CABOT CORP reports it. History and quarterly detail are in the app.
- Reinforcement Materials$2.3B
- Performance Chemicals$1.3B
Leadership changes
From CABOT CORP's own filings, the day they're filed.
- Matthew Wood · President · departureeff. 2026-01-05
- Hobart C. Kalkstein · President · departureeff. 2025-06-15
- Thierry Vanlancker · director · appointmenteff. 2024-07-12
Latest filings
- 8-K · Company announcement2026-08-21
- 8-K · Company announcement2026-08-14
- 10-Q · Quarterly report2026-08-04
- 8-K · Company announcement2026-08-03
- 8-K · Company announcement2026-07-30
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about CABOT CORP, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.